PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Pitolisant hydrochloride - Narcolepsy

PAD Profile : Pitolisant hydrochloride - Narcolepsy

Keywords :
fatigue, sleepiness, cataplexy
Brand Names Include :
Wakix

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
08 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee recommends pitolisant (Wakix®) monotherapy for the management of narcolepsy with or without cataplexy.

The APC recommend a RED traffic light status for the use of pitolisant monotherapy for this indication.

Combination treatment will not be routinely funded and if combination treatment is considered clinically appropriate, an individual funding request (IFR) will need to be completed by the specialist for consideration of commissioner funding.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

04. Central Nervous System
04.04.00. CNS stimulants and drugs used for ADHD
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More